urea has been researched along with Auricular Fibrillation in 91 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction." | 9.51 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. ( Claggett, BL; Corbalan, R; Diaz, R; Felker, GM; Filippatos, G; Goudev, AR; Heitner, SB; Kupfer, S; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Miao, ZM; Serpytis, P; Solomon, SD; Suter, T; Teerlink, JR; Yilmaz, MB; Zannad, F, 2022) |
| "To investigate the efficacy of prophylactic administration of low-dose landiolol on postoperative atrial fibrillation (POAF) in patients after cardiovascular surgery." | 9.34 | Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study). ( Akiyama, M; Ito, K; Kaiho, Y; Katahira, S; Kumagai, K; Maeda, K; Matsuo, S; Saiki, Y; Sasaki, K; Sugawara, Y; Suzuki, T; Suzuki, Y; Tsuji, I, 2020) |
| "We investigated for the first time the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial fibrillation/atrial flutter (AF/AFL) in Caucasian patients." | 9.30 | Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients. ( Domanovits, H; Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Stix, G; Trebs, M; Unger, M; Wolzt, M, 2019) |
| "Perioperative landiolol administration suppressed the incidence of new-onset of AF as well as sinus tachycardia, and the plasma IL-6 elevation in patients undergoing esophageal cancer surgery." | 9.24 | The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial. ( Goyagi, T; Horiguchi, T; Horikoshi, Y; Kodama, S; Kudo, R; Nishikawa, T, 2017) |
| "The study was designed and designated the "HEARTFUL study" in the hope of establishing a basis for control of HEART rate in inFant and child tachyarrhythmia Using Landiolol in children with heart failure." | 9.24 | Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial. ( Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J, 2017) |
| " Postoperative atrial fibrillation occurred in 15 patients (30 per cent) receiving placebo versus five (10 per cent) receiving landiolol (P = 0·012)." | 9.24 | Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. ( Hayata, K; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H, 2017) |
| "We aimed to determine whether intraoperative low-dose infusion of landiolol, an ultra-short-acting beta blocker, can prevent postoperative atrial fibrillation (POAF) after lung resection." | 9.22 | Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. ( Aoyama, H; Aoyama, Y; Otsuka, Y, 2016) |
| "Considering this analysis, landiolol was effective in the prevention of AF after cardiothoracic surgery and did not increase the risk of major postoperative complications." | 9.22 | Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis. ( Chen, C; Hao, J; Liu, L; Peng, H; Xu, W; Zhang, J; Zhou, J, 2022) |
| "Low-dose infusion of landiolol hydrochloride prevented atrial fibrillation after cardiac surgery in patients with cardiac dysfunction and was safe, with no effect on blood pressure." | 9.20 | Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventric ( Arimoto, M; Hata, H; Ishii, Y; Osaka, S; Sezai, A; Shiono, M; Yaoita, H, 2015) |
| "The goal of this prospective study was to examine the effects of landiolol hydrochloride on prevention of atrial fibrillation and on hemodynamics in the acute postoperative phase after heart valve surgery." | 9.16 | Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. ( Hirai, H; Hosono, M; Nakahira, A; Sakaguchi, M; Sasaki, Y; Seo, H; Suehiro, S, 2012) |
| "We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF)." | 9.16 | Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. ( Hata, M; Hirayama, A; Kunimoto, S; Nakai, T; Sezai, A; Shiono, M; Yoshitake, I, 2012) |
| "Postoperative intravenous landiolol therapy followed by oral carvedilol may be more effective than oral carvedilol alone for prevention of atrial fibrillation after off-pump CABG." | 9.16 | Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. ( Bessho, R; Fujii, M; Ochi, M; Shimizu, K; Takeda, S; Terajima, K, 2012) |
| "Postoperative atrial fibrillation was reduced by treatment with landiolol hydrochloride." | 9.15 | Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. ( Hata, M; Hirayama, A; Minami, K; Nakai, T; Sezai, A; Shiono, M; Wakui, S; Yoshitake, I, 2011) |
| "Landiolol versus SoC in prevention of atrial fibrillation immediately after cardiac surgery." | 9.05 | Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System. ( Heringlake, M; Walter, E, 2020) |
| "Despite the increasing application of tolvaptan in cardiac surgery, there is no information on the use of tolvaptan in Stanford patients with type A aortic dissection." | 8.31 | Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection. ( Gao, F; Gao, Y; He, X; Liu, W; Shi, L; Wang, W; Zhuang, X, 2023) |
| "Landiolol enables us to treat the patients with rapid atrial fibrillation (AF) with acute decompensated heart failure (ADHF) efficiently." | 8.12 | Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment. ( Abe, T; Ebina, T; Hanajima, Y; Hibi, K; Horii, M; Iwahashi, N; Kimura, K; Kimura, Y; Kirigaya, J; Kosuge, M; Matsuzawa, Y; Minamimoto, Y; Okada, K; Takahashi, H; Tamura, K, 2022) |
| "The HEARTFUL study has demonstrated the efficacy of landiolol, by reducing heart rate or terminating tachycardia, in pediatric patients with supraventricular tachyarrhythmias." | 8.12 | Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study. ( Aoki, H; Fukunaga, H; Horigome, H; Miura, M; Miyazaki, A; Morishima, E; Ohashi, N; Oki, K; Ono, H; Sagawa, K; Sakaguchi, H; Sato, S; Sumitomo, N; Suzuki, T; Takei, K; Ueda, H, 2022) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 8.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "Clinical experience with landiolol use in patients with atrial fibrillation (AF) and a severely depressed left ventricular (LV) function is limited." | 7.96 | Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function. ( Akitsu, K; Fujino, T; Ikeda, T; Kinoshita, T; Koike, H; Shinohara, M; Suzuki, T; Wada, R; Yano, K, 2020) |
| "2%) received landiolol for atrial fibrillation." | 7.91 | A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. ( Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T, 2019) |
| "The authors assessed the efficacy and safety of landiolol, an ultra-short-acting beta-blocker, with those of amiodarone in the restoration of sinus rhythm for postoperative atrial fibrillation (POAF) in intensive care unit (ICU) patients." | 7.83 | Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients. ( Fujino, Y; Ohta, N; Shibata, SC; Uchiyama, A, 2016) |
| "Landiolol hydrochloride can be effectively and safely used in patients who develop tachyarrhythmia after esophagectomy." | 7.80 | Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. ( Fujii, T; Fujiwara, M; Iwata, N; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Niwa, Y; Sugimoto, H; Tanaka, C, 2014) |
| "The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF)." | 7.80 | Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. ( Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A, 2014) |
| "The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 7.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
| "Low-dose landiolol can be effective quickly and used safely in patients who develop atrial fibrillation after pulmonary resection for lung cancer." | 7.77 | Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. ( Funakoshi, Y; Maeda, H; Maekura, R; Nojiri, T; Okumura, M; Takeuchi, Y; Yamamoto, K, 2011) |
| "Intra-operative low-dose infusion of landiolol hydrochloride decreases the incidence of postoperative atrial fibrillation after OPCAB." | 7.76 | [Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting]. ( Kurosawa, H; Sato, Y; Seto, Y; Takase, S; Wakamatsu, H; Yokoyama, H, 2010) |
| "Intraoperative and perioperative administration of low-dose landiolol has a preventive effect on the appearance of atrial fibrillation after CABG surgery." | 7.75 | Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery. ( Fujiwara, H; Kawamura, T; Namai, A; Sakurai, M, 2009) |
| "Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting." | 7.75 | Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. ( Kawamura, T; Namai, A; Sakurai, M; Yoshioka, I, 2009) |
| "The purpose of this study was to investigate the efficacy of landiolol hydrochloride, a short-acting beta(1) blocker, by initiating its administration at a low dose (5 microg kg(-1) min(-1)) in patients with postoperative supraventricular arrhythmia." | 7.75 | Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. ( Fukutomi, T; Nishimori, H; Radhakrishnan, G; Sasaguri, S; Wariishi, S; Yamamoto, M; Yamashita, K, 2009) |
| "We examined the effect of landiolol hydrochloride, a selective beta1-adrenoreceptor antagonist, on the incidence of atrial fibrillation(AF)." | 7.74 | [Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection]. ( Ishimura, N; Kumano, H; Morioka, M; Nishiwada, M; Okita, T; Shinjo, T; Uji, M, 2008) |
| " During the intraoperative discrepancy between heart rate and pulse rate, continuous infusion of low dose landiolol was useful to control his heart rate of atrial fibrillation." | 7.73 | [Effect of landiolol on heart rate control of atrial fibrillation in a patient with sick sinus syndrome under ventricular pacing]. ( Kitoh, T; Kobayashi, K; Otagiri, T; Satoh, N, 2006) |
| "Landiolol is a recently innovated ultra-short-acting beta-blocker with 251-fold β1/β2 selectivity, which was originally indicated only to control peri-operative supra-ventricular tachyarrhythmia by 2013 in Japan." | 6.66 | Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ( Imamura, T; Kinugawa, K, 2020) |
| "Landiolol is an ultra-short acting beta-blocker, and some randomized controlled trials of landiolol administration for the prevention of POAF have been conducted in Japan." | 6.50 | Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. ( Hamasaki, T; Kitakaze, M; Sakamoto, A, 2014) |
| " No adverse effects were reported in any patient." | 5.62 | Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies. ( Ashida, A; Kishi, K; Konishi, H; Nemoto, S; Odanaka, Y; Ozaki, N, 2021) |
| "In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction." | 5.51 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. ( Claggett, BL; Corbalan, R; Diaz, R; Felker, GM; Filippatos, G; Goudev, AR; Heitner, SB; Kupfer, S; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Miao, ZM; Serpytis, P; Solomon, SD; Suter, T; Teerlink, JR; Yilmaz, MB; Zannad, F, 2022) |
| "Landiolol was ineffective in the majority of AFl/AT patients." | 5.51 | Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction. ( Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K, 2019) |
| "Thyroid storm is a life-threatening disorder that remains a therapeutic challenge." | 5.46 | Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017) |
| "The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min." | 5.43 | Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016) |
| "The patient was a 20-year old male with dilated cardiomyopathy." | 5.42 | An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension. ( Amiya, E; Endo, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Nitta, D, 2015) |
| "Landiolol hydrochloride was the first-line treatment in 46 patients and the only therapy in 26 patients." | 5.39 | Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. ( Fukushima, S; Kuratani, T; Miyagawa, S; Nishi, H; Saito, S; Sakaguchi, T; Sawa, Y; Ueno, T; Yoshikawa, Y, 2013) |
| "Landiolol hydrochloride is a new β-adrenergic blocker with a pharmacological profile that suggests it can be administered safely to patients who have sinus tachycardia or tachyarrhythmia and who require heart rate reduction." | 5.39 | Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. ( Kim, C; Kohda, S; Nakanishi, K; Sakamoto, A; Takeda, S, 2013) |
| "When landiolol was administered, enough attention should be paid to the patients whose left ventricular function was low." | 5.36 | [Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?]. ( Abe, T; Fukuda, T; Haruna, T; Inoko, M; Ito, H; Miyamoto, S; Nakane, E; Nohara, R; Sasaki, K; Uehara, K; Ueyama, K, 2010) |
| "To investigate the efficacy of prophylactic administration of low-dose landiolol on postoperative atrial fibrillation (POAF) in patients after cardiovascular surgery." | 5.34 | Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study). ( Akiyama, M; Ito, K; Kaiho, Y; Katahira, S; Kumagai, K; Maeda, K; Matsuo, S; Saiki, Y; Sasaki, K; Sugawara, Y; Suzuki, T; Suzuki, Y; Tsuji, I, 2020) |
| "A 71-year-old woman with a history of persistent atrial fibrillation underwent clipping of a ruptured cerebral artery aneurysm." | 5.32 | Conversion of atrial fibrillation to sinus rhythm during landiolol infusion. ( Goto, M; Isomine, S; Kanazawa, T; Mayahara, T; Nakajima, H; Sakaida, K; Sato, M, 2004) |
| "We investigated for the first time the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial fibrillation/atrial flutter (AF/AFL) in Caucasian patients." | 5.30 | Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients. ( Domanovits, H; Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Stix, G; Trebs, M; Unger, M; Wolzt, M, 2019) |
| "The study was designed and designated the "HEARTFUL study" in the hope of establishing a basis for control of HEART rate in inFant and child tachyarrhythmia Using Landiolol in children with heart failure." | 5.24 | Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial. ( Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J, 2017) |
| "Perioperative landiolol administration suppressed the incidence of new-onset of AF as well as sinus tachycardia, and the plasma IL-6 elevation in patients undergoing esophageal cancer surgery." | 5.24 | The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial. ( Goyagi, T; Horiguchi, T; Horikoshi, Y; Kodama, S; Kudo, R; Nishikawa, T, 2017) |
| " Postoperative atrial fibrillation occurred in 15 patients (30 per cent) receiving placebo versus five (10 per cent) receiving landiolol (P = 0·012)." | 5.24 | Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. ( Hayata, K; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H, 2017) |
| "Considering this analysis, landiolol was effective in the prevention of AF after cardiothoracic surgery and did not increase the risk of major postoperative complications." | 5.22 | Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis. ( Chen, C; Hao, J; Liu, L; Peng, H; Xu, W; Zhang, J; Zhou, J, 2022) |
| "We aimed to determine whether intraoperative low-dose infusion of landiolol, an ultra-short-acting beta blocker, can prevent postoperative atrial fibrillation (POAF) after lung resection." | 5.22 | Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. ( Aoyama, H; Aoyama, Y; Otsuka, Y, 2016) |
| "Low-dose infusion of landiolol hydrochloride prevented atrial fibrillation after cardiac surgery in patients with cardiac dysfunction and was safe, with no effect on blood pressure." | 5.20 | Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventric ( Arimoto, M; Hata, H; Ishii, Y; Osaka, S; Sezai, A; Shiono, M; Yaoita, H, 2015) |
| "Results from the multicenter trial (J-Land study) of landiolol versus digoxin in atrial fibrillation (AF) and atrial flutter (AFL) patients with left ventricular (LV) dysfunction revealed that landiolol was more effective for controlling rapid HR than digoxin." | 5.19 | Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. ( Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T, 2014) |
| "The incidence of atrial fibrillation was significantly lower in the landiolol group compared to the control group (13/68, 19% vs." | 5.17 | Perioperative use of a beta blocker in coronary artery bypass grafting. ( Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y, 2013) |
| "We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF)." | 5.16 | Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. ( Hata, M; Hirayama, A; Kunimoto, S; Nakai, T; Sezai, A; Shiono, M; Yoshitake, I, 2012) |
| "The goal of this prospective study was to examine the effects of landiolol hydrochloride on prevention of atrial fibrillation and on hemodynamics in the acute postoperative phase after heart valve surgery." | 5.16 | Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. ( Hirai, H; Hosono, M; Nakahira, A; Sakaguchi, M; Sasaki, Y; Seo, H; Suehiro, S, 2012) |
| "Postoperative intravenous landiolol therapy followed by oral carvedilol may be more effective than oral carvedilol alone for prevention of atrial fibrillation after off-pump CABG." | 5.16 | Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. ( Bessho, R; Fujii, M; Ochi, M; Shimizu, K; Takeda, S; Terajima, K, 2012) |
| "Postoperative atrial fibrillation was reduced by treatment with landiolol hydrochloride." | 5.15 | Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. ( Hata, M; Hirayama, A; Minami, K; Nakai, T; Sezai, A; Shiono, M; Wakui, S; Yoshitake, I, 2011) |
| " In paroxysmal atrial fibrillation, landiolol hydrochloride reduced the heart rate from 111 +/- 20 to 90 +/- 10/min." | 5.09 | Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. ( Atarashi, H; Endoh, Y; Hayakawa, H; Ino, T; Kuruma, A; Saitoh, H; Yashima, M, 2000) |
| "Landiolol versus SoC in prevention of atrial fibrillation immediately after cardiac surgery." | 5.05 | Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System. ( Heringlake, M; Walter, E, 2020) |
| "Despite the increasing application of tolvaptan in cardiac surgery, there is no information on the use of tolvaptan in Stanford patients with type A aortic dissection." | 4.31 | Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection. ( Gao, F; Gao, Y; He, X; Liu, W; Shi, L; Wang, W; Zhuang, X, 2023) |
| "Landiolol enables us to treat the patients with rapid atrial fibrillation (AF) with acute decompensated heart failure (ADHF) efficiently." | 4.12 | Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment. ( Abe, T; Ebina, T; Hanajima, Y; Hibi, K; Horii, M; Iwahashi, N; Kimura, K; Kimura, Y; Kirigaya, J; Kosuge, M; Matsuzawa, Y; Minamimoto, Y; Okada, K; Takahashi, H; Tamura, K, 2022) |
| "The HEARTFUL study has demonstrated the efficacy of landiolol, by reducing heart rate or terminating tachycardia, in pediatric patients with supraventricular tachyarrhythmias." | 4.12 | Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study. ( Aoki, H; Fukunaga, H; Horigome, H; Miura, M; Miyazaki, A; Morishima, E; Ohashi, N; Oki, K; Ono, H; Sagawa, K; Sakaguchi, H; Sato, S; Sumitomo, N; Suzuki, T; Takei, K; Ueda, H, 2022) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 4.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "Clinical experience with landiolol use in patients with atrial fibrillation (AF) and a severely depressed left ventricular (LV) function is limited." | 3.96 | Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function. ( Akitsu, K; Fujino, T; Ikeda, T; Kinoshita, T; Koike, H; Shinohara, M; Suzuki, T; Wada, R; Yano, K, 2020) |
| "2%) received landiolol for atrial fibrillation." | 3.91 | A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. ( Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T, 2019) |
| "The authors assessed the efficacy and safety of landiolol, an ultra-short-acting beta-blocker, with those of amiodarone in the restoration of sinus rhythm for postoperative atrial fibrillation (POAF) in intensive care unit (ICU) patients." | 3.83 | Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients. ( Fujino, Y; Ohta, N; Shibata, SC; Uchiyama, A, 2016) |
| "Landiolol hydrochloride can be effectively and safely used in patients who develop tachyarrhythmia after esophagectomy." | 3.80 | Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. ( Fujii, T; Fujiwara, M; Iwata, N; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Niwa, Y; Sugimoto, H; Tanaka, C, 2014) |
| "The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF)." | 3.80 | Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. ( Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A, 2014) |
| "continuous administration of landiolol at a low dose after off-pump coronary artery bypass reduced the incidence of atrial fibrillation." | 3.79 | Effect of landiolol hydrochloride after off-pump coronary artery bypass. ( Ishitoya, H; Maisawa, K; Shimamura, Y; Yamazaki, K, 2013) |
| "The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 3.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
| "Low-dose landiolol can be effective quickly and used safely in patients who develop atrial fibrillation after pulmonary resection for lung cancer." | 3.77 | Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. ( Funakoshi, Y; Maeda, H; Maekura, R; Nojiri, T; Okumura, M; Takeuchi, Y; Yamamoto, K, 2011) |
| "Intra-operative low-dose infusion of landiolol hydrochloride decreases the incidence of postoperative atrial fibrillation after OPCAB." | 3.76 | [Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting]. ( Kurosawa, H; Sato, Y; Seto, Y; Takase, S; Wakamatsu, H; Yokoyama, H, 2010) |
| "Intraoperative and perioperative administration of low-dose landiolol has a preventive effect on the appearance of atrial fibrillation after CABG surgery." | 3.75 | Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery. ( Fujiwara, H; Kawamura, T; Namai, A; Sakurai, M, 2009) |
| "The purpose of this study was to investigate the efficacy of landiolol hydrochloride, a short-acting beta(1) blocker, by initiating its administration at a low dose (5 microg kg(-1) min(-1)) in patients with postoperative supraventricular arrhythmia." | 3.75 | Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. ( Fukutomi, T; Nishimori, H; Radhakrishnan, G; Sasaguri, S; Wariishi, S; Yamamoto, M; Yamashita, K, 2009) |
| "Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting." | 3.75 | Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. ( Kawamura, T; Namai, A; Sakurai, M; Yoshioka, I, 2009) |
| "We examined the effect of landiolol hydrochloride, a selective beta1-adrenoreceptor antagonist, on the incidence of atrial fibrillation(AF)." | 3.74 | [Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection]. ( Ishimura, N; Kumano, H; Morioka, M; Nishiwada, M; Okita, T; Shinjo, T; Uji, M, 2008) |
| " During the intraoperative discrepancy between heart rate and pulse rate, continuous infusion of low dose landiolol was useful to control his heart rate of atrial fibrillation." | 3.73 | [Effect of landiolol on heart rate control of atrial fibrillation in a patient with sick sinus syndrome under ventricular pacing]. ( Kitoh, T; Kobayashi, K; Otagiri, T; Satoh, N, 2006) |
| "Landiolol is a recently innovated ultra-short-acting beta-blocker with 251-fold β1/β2 selectivity, which was originally indicated only to control peri-operative supra-ventricular tachyarrhythmia by 2013 in Japan." | 2.66 | Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ( Imamura, T; Kinugawa, K, 2020) |
| "Landiolol is an ultra-short acting beta-blocker, and some randomized controlled trials of landiolol administration for the prevention of POAF have been conducted in Japan." | 2.50 | Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. ( Hamasaki, T; Kitakaze, M; Sakamoto, A, 2014) |
| "Landiolol is an intravenous, selective beta-1-receptor blocking agent with rapid onset of action and ultra-short half-life that has a predominant negative chronotropic and only mild negative inotropic effect without significant reduction of blood pressure." | 1.72 | The application of landiolol in the cardiovascular and intensive care ( Fejér, C; Gellér, L; Kiss, B; Kovács, E; Merkely, B; Pilecky, D; Radics, P; Ruzsa, Z; Straub, É; Zima, E, 2022) |
| " No adverse effects were reported in any patient." | 1.62 | Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies. ( Ashida, A; Kishi, K; Konishi, H; Nemoto, S; Odanaka, Y; Ozaki, N, 2021) |
| "Landiolol was ineffective in the majority of AFl/AT patients." | 1.51 | Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction. ( Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K, 2019) |
| "Thyroid storm is a life-threatening disorder that remains a therapeutic challenge." | 1.46 | Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017) |
| "The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min." | 1.43 | Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016) |
| "The patient was a 20-year old male with dilated cardiomyopathy." | 1.42 | An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension. ( Amiya, E; Endo, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Nitta, D, 2015) |
| "Landiolol hydrochloride was the first-line treatment in 46 patients and the only therapy in 26 patients." | 1.39 | Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. ( Fukushima, S; Kuratani, T; Miyagawa, S; Nishi, H; Saito, S; Sakaguchi, T; Sawa, Y; Ueno, T; Yoshikawa, Y, 2013) |
| "Landiolol hydrochloride is a new β-adrenergic blocker with a pharmacological profile that suggests it can be administered safely to patients who have sinus tachycardia or tachyarrhythmia and who require heart rate reduction." | 1.39 | Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. ( Kim, C; Kohda, S; Nakanishi, K; Sakamoto, A; Takeda, S, 2013) |
| "When landiolol was administered, enough attention should be paid to the patients whose left ventricular function was low." | 1.36 | [Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?]. ( Abe, T; Fukuda, T; Haruna, T; Inoko, M; Ito, H; Miyamoto, S; Nakane, E; Nohara, R; Sasaki, K; Uehara, K; Ueyama, K, 2010) |
| "Landiolol hydrochloride was administered continuously until the morning of the following day and sinus rhythm was maintained postoperatively." | 1.36 | Conversion of atrial flutter to sinus rhythm during landiolol infusion. ( Goto, K; Noguchi, T; Ohchi, Y; Shingu, C; Yamamoto, S; Yasuda, N, 2010) |
| "Landiolol is a short-acting beta-blocker, with high beta 1-selectivity and a short duration of action." | 1.35 | Clinical role and efficacy of landiolol in the intensive care unit. ( Akada, S; Hongo, T; Miyagi, Y; Sakamoto, A; Sato, C; Takeda, S; Tanaka, K; Terajima, K; Yoshida, Y, 2008) |
| "A 71-year-old woman with a history of persistent atrial fibrillation underwent clipping of a ruptured cerebral artery aneurysm." | 1.32 | Conversion of atrial fibrillation to sinus rhythm during landiolol infusion. ( Goto, M; Isomine, S; Kanazawa, T; Mayahara, T; Nakajima, H; Sakaida, K; Sato, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.10) | 18.7374 |
| 1990's | 1 (1.10) | 18.2507 |
| 2000's | 15 (16.48) | 29.6817 |
| 2010's | 55 (60.44) | 24.3611 |
| 2020's | 19 (20.88) | 2.80 |
| Authors | Studies |
|---|---|
| Iwahashi, N | 1 |
| Kirigaya, J | 1 |
| Abe, T | 2 |
| Horii, M | 1 |
| Takahashi, H | 1 |
| Hanajima, Y | 1 |
| Kimura, Y | 1 |
| Minamimoto, Y | 1 |
| Okada, K | 1 |
| Matsuzawa, Y | 1 |
| Hibi, K | 1 |
| Kosuge, M | 1 |
| Ebina, T | 1 |
| Tamura, K | 2 |
| Kimura, K | 1 |
| Radics, P | 1 |
| Kiss, B | 1 |
| Kovács, E | 1 |
| Pilecky, D | 1 |
| Ruzsa, Z | 1 |
| Straub, É | 1 |
| Fejér, C | 1 |
| Gellér, L | 1 |
| Merkely, B | 1 |
| Zima, E | 1 |
| Solomon, SD | 1 |
| Claggett, BL | 1 |
| Miao, ZM | 1 |
| Diaz, R | 1 |
| Felker, GM | 1 |
| McMurray, JJV | 1 |
| Metra, M | 1 |
| Corbalan, R | 1 |
| Filippatos, G | 1 |
| Goudev, AR | 1 |
| Mareev, V | 1 |
| Serpytis, P | 1 |
| Suter, T | 1 |
| Yilmaz, MB | 1 |
| Zannad, F | 1 |
| Kupfer, S | 1 |
| Heitner, SB | 1 |
| Malik, FI | 1 |
| Teerlink, JR | 1 |
| Ferraris, A | 2 |
| Jacquet-Lagrèze, M | 2 |
| Cazenave, L | 2 |
| Fornier, W | 2 |
| Jalalzai, W | 2 |
| Rousseau-Saine, N | 2 |
| Pozzi, M | 2 |
| Fellahi, JL | 2 |
| van der Meer, P | 1 |
| Rienstra, M | 2 |
| van Veldhuisen, DJ | 1 |
| Sagawa, K | 2 |
| Suzuki, T | 4 |
| Takei, K | 1 |
| Miura, M | 2 |
| Ueda, H | 2 |
| Horigome, H | 2 |
| Ono, H | 2 |
| Ohashi, N | 2 |
| Sato, S | 1 |
| Fukunaga, H | 1 |
| Aoki, H | 1 |
| Miyazaki, A | 2 |
| Sakaguchi, H | 2 |
| Morishima, E | 1 |
| Oki, K | 1 |
| Sumitomo, N | 2 |
| Wang, W | 2 |
| Gao, F | 2 |
| He, X | 2 |
| Gao, Y | 3 |
| Shi, L | 1 |
| Liu, W | 2 |
| Zhuang, X | 1 |
| Kawakami, A | 1 |
| Kobayashi, Y | 1 |
| Katsube, T | 1 |
| Gassanov, N | 1 |
| Er, F | 1 |
| Stix, G | 1 |
| Wolzt, M | 1 |
| Domanovits, H | 1 |
| Kadlecová, P | 1 |
| Husch, B | 1 |
| Trebs, M | 1 |
| Hodisch, J | 1 |
| Unger, M | 1 |
| Krumpl, G | 1 |
| Walter, E | 1 |
| Heringlake, M | 1 |
| O'Brien, B | 1 |
| Muehlschlegel, JD | 1 |
| Sasaki, K | 2 |
| Kumagai, K | 1 |
| Maeda, K | 2 |
| Akiyama, M | 1 |
| Ito, K | 1 |
| Matsuo, S | 1 |
| Katahira, S | 1 |
| Suzuki, Y | 2 |
| Kaiho, Y | 1 |
| Sugawara, Y | 1 |
| Tsuji, I | 1 |
| Saiki, Y | 1 |
| Imamura, T | 3 |
| Kinugawa, K | 3 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 10 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 4 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Li, Y | 5 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 3 |
| Yan, Z | 2 |
| Wang, Y | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, J | 7 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 3 |
| Zhang, L | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 5 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 5 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 4 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 2 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Shinohara, M | 1 |
| Wada, R | 1 |
| Yano, K | 1 |
| Akitsu, K | 1 |
| Koike, H | 1 |
| Kinoshita, T | 1 |
| Fujino, T | 1 |
| Ikeda, T | 2 |
| Hariri, G | 1 |
| Urbina, T | 1 |
| Mazerand, S | 1 |
| Bige, N | 1 |
| Baudel, JL | 1 |
| Ait-Oufella, H | 1 |
| Takahashi, K | 2 |
| Sakaue, T | 1 |
| Enomoto, D | 1 |
| Uemura, S | 1 |
| Okura, T | 1 |
| Ikeda, S | 1 |
| Takemoto, M | 1 |
| Utsunomiya, Y | 1 |
| Hyodo, T | 1 |
| Allaouchiche, B | 1 |
| Junot, S | 1 |
| Ashida, A | 2 |
| Ozaki, N | 1 |
| Kishi, K | 1 |
| Odanaka, Y | 1 |
| Nemoto, S | 1 |
| Konishi, H | 1 |
| Hao, J | 1 |
| Zhou, J | 1 |
| Xu, W | 1 |
| Chen, C | 1 |
| Peng, H | 1 |
| Horikoshi, Y | 1 |
| Goyagi, T | 1 |
| Kudo, R | 1 |
| Kodama, S | 1 |
| Horiguchi, T | 1 |
| Nishikawa, T | 1 |
| Ojima, T | 2 |
| Nakamori, M | 2 |
| Nakamura, M | 2 |
| Katsuda, M | 2 |
| Hayata, K | 2 |
| Kato, T | 1 |
| Kitadani, J | 1 |
| Tabata, H | 1 |
| Takeuchi, A | 1 |
| Yamaue, H | 2 |
| Godo, S | 1 |
| Kawazoe, Y | 1 |
| Ozaki, H | 1 |
| Fujita, M | 1 |
| Kudo, D | 1 |
| Nomura, R | 1 |
| Shimokawa, H | 1 |
| Kushimoto, S | 1 |
| Tamura, T | 1 |
| Yatabe, T | 1 |
| Yokoyama, M | 1 |
| Syed, YY | 1 |
| Kugo, Y | 1 |
| Nishi, H | 2 |
| Sekiya, N | 1 |
| Yamada, M | 1 |
| Takahashi, T | 1 |
| Hajibandeh, S | 2 |
| Melhado, R | 1 |
| Akhtar, K | 1 |
| Trivedi, V | 1 |
| Asaad, P | 1 |
| Oka, E | 2 |
| Iwasaki, YK | 2 |
| Maru, E | 1 |
| Fujimoto, Y | 1 |
| Ito-Hagiwara, K | 1 |
| Hayashi, H | 1 |
| Yamamoto, T | 1 |
| Yodogawa, K | 1 |
| Hayashi, M | 1 |
| Shimizu, W | 3 |
| Nitta, D | 2 |
| Yamashita, T | 3 |
| Nakasu, Y | 1 |
| Mizutani, H | 1 |
| Sumitani, K | 1 |
| Nagaoka, E | 1 |
| Arai, H | 1 |
| Makita, S | 1 |
| Miyagi, N | 1 |
| Iwahashi, M | 1 |
| Iida, T | 1 |
| Adachi, T | 1 |
| Sato, A | 1 |
| Baba, M | 1 |
| Hiraya, D | 1 |
| Hasegawa, T | 1 |
| Kuroki, K | 1 |
| Hoshi, T | 1 |
| Aonuma, K | 1 |
| Kobayashi, S | 1 |
| Murakami, W | 1 |
| Myoren, T | 1 |
| Tateishi, H | 1 |
| Okuda, S | 1 |
| Doi, M | 1 |
| Nao, T | 1 |
| Wada, Y | 1 |
| Matsuzaki, M | 1 |
| Yano, M | 1 |
| Maisawa, K | 1 |
| Yamazaki, K | 1 |
| Ishitoya, H | 1 |
| Shimamura, Y | 1 |
| Ogawa, S | 1 |
| Okawa, Y | 1 |
| Goto, Y | 1 |
| Aoki, M | 1 |
| Baba, H | 1 |
| Nagai, R | 1 |
| Inoue, H | 1 |
| Atarashi, H | 2 |
| Seino, Y | 1 |
| Aiba, T | 1 |
| Kitakaze, M | 3 |
| Sakamoto, A | 6 |
| Imai, Y | 1 |
| Daimon, T | 1 |
| Fujino, K | 1 |
| Nagano, T | 2 |
| Okamura, T | 1 |
| Hori, M | 1 |
| Liu, S | 1 |
| Bian, C | 1 |
| Jian, Y | 1 |
| Hamasaki, T | 1 |
| Sezai, A | 4 |
| Shiono, M | 4 |
| Osumi, M | 1 |
| Tashiro, T | 2 |
| Morita, Y | 1 |
| Kamiya, S | 1 |
| Minematsu, N | 2 |
| Nishimi, M | 2 |
| Wada, H | 1 |
| Niwa, Y | 1 |
| Koike, M | 1 |
| Iwata, N | 1 |
| Kobayashi, D | 1 |
| Tanaka, C | 1 |
| Fujii, T | 1 |
| Nakayama, G | 1 |
| Sugimoto, H | 1 |
| Fujiwara, M | 1 |
| Kodera, Y | 1 |
| Saitoh, T | 1 |
| Matsushita, M | 1 |
| Yamashita, Y | 1 |
| Iguchi, M | 1 |
| Nakatani, R | 1 |
| Usui, T | 1 |
| Takagi, D | 1 |
| Hamatani, Y | 1 |
| Unoki, T | 1 |
| Ishii, M | 1 |
| Ogawa, H | 1 |
| Masunaga, N | 1 |
| Abe, M | 1 |
| Akao, M | 1 |
| Melby, SJ | 1 |
| Osaka, S | 1 |
| Yaoita, H | 1 |
| Ishii, Y | 1 |
| Arimoto, M | 1 |
| Hata, H | 1 |
| Endo, M | 1 |
| Amiya, E | 1 |
| Inaba, T | 1 |
| Maki, H | 1 |
| Hatano, M | 1 |
| Komuro, I | 1 |
| Shibata, SC | 1 |
| Uchiyama, A | 1 |
| Ohta, N | 1 |
| Fujino, Y | 1 |
| Allende, M | 1 |
| Molina, E | 1 |
| Guruceaga, E | 1 |
| Tamayo, I | 1 |
| González-Porras, JR | 1 |
| Gonzalez-López, TJ | 1 |
| Toledo, E | 1 |
| Rabal, O | 1 |
| Ugarte, A | 1 |
| Roldán, V | 1 |
| Rivera, J | 1 |
| Oyarzabal, J | 1 |
| Montes, R | 1 |
| Hermida, J | 1 |
| Spronk, HM | 1 |
| De Jong, AM | 1 |
| Verheule, S | 1 |
| De Boer, HC | 1 |
| Maass, AH | 1 |
| Lau, DH | 1 |
| van Hunnik, A | 1 |
| Kuiper, M | 1 |
| Lumeij, S | 1 |
| Zeemering, S | 1 |
| Linz, D | 1 |
| Kamphuisen, PW | 1 |
| Ten Cate, H | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| van Zonneveld, AJ | 1 |
| Schotten, U | 1 |
| Ji, T | 1 |
| Feng, C | 1 |
| Sun, L | 1 |
| Ye, X | 1 |
| Bai, Y | 1 |
| Qin, Y | 1 |
| Zhao, X | 1 |
| Takata, J | 1 |
| Haruyama, N | 1 |
| Arashi, T | 1 |
| Mae, T | 1 |
| Nakamura, K | 1 |
| Inokuchi, R | 1 |
| Hiruma, T | 1 |
| Tokunaga, K | 1 |
| Doi, K | 1 |
| Nakajima, S | 1 |
| Aoyama, H | 1 |
| Otsuka, Y | 1 |
| Aoyama, Y | 1 |
| Takigiku, K | 1 |
| Yoshimoto, J | 1 |
| Ushinohama, H | 1 |
| Iwamoto, M | 1 |
| Takamuro, M | 1 |
| Tokunaga, C | 1 |
| Mene-Afejuku, TO | 1 |
| Balogun, MO | 1 |
| Akintomide, AO | 1 |
| Adebayo, RA | 1 |
| Yano, T | 1 |
| Iwasaki, T | 1 |
| Naruo, H | 1 |
| Tsuneyoshi, I | 1 |
| Okita, T | 1 |
| Uji, M | 1 |
| Shinjo, T | 1 |
| Morioka, M | 1 |
| Kumano, H | 1 |
| Ishimura, N | 1 |
| Nishiwada, M | 1 |
| Ambwani, J | 1 |
| Ubhrani, D | 1 |
| Saad, R | 1 |
| Dunning, J | 1 |
| Fujiwara, H | 1 |
| Sakurai, M | 2 |
| Namai, A | 2 |
| Kawamura, T | 2 |
| Wariishi, S | 1 |
| Yamashita, K | 1 |
| Nishimori, H | 1 |
| Fukutomi, T | 1 |
| Yamamoto, M | 1 |
| Radhakrishnan, G | 1 |
| Sasaguri, S | 1 |
| Yoshioka, I | 1 |
| Yamamoto, S | 1 |
| Goto, K | 1 |
| Ohchi, Y | 1 |
| Yasuda, N | 1 |
| Shingu, C | 1 |
| Noguchi, T | 1 |
| Tanaka, K | 2 |
| Uehara, K | 1 |
| Ueyama, K | 1 |
| Ito, H | 1 |
| Fukuda, T | 1 |
| Nakane, E | 1 |
| Miyamoto, S | 1 |
| Haruna, T | 1 |
| Inoko, M | 1 |
| Nohara, R | 1 |
| Wakamatsu, H | 1 |
| Takase, S | 1 |
| Sato, Y | 1 |
| Seto, Y | 1 |
| Kurosawa, H | 1 |
| Yokoyama, H | 1 |
| Minami, K | 1 |
| Nakai, T | 2 |
| Hata, M | 2 |
| Yoshitake, I | 2 |
| Wakui, S | 1 |
| Hirayama, A | 2 |
| Nakano, T | 1 |
| Shimizu, K | 2 |
| Kawashima, O | 1 |
| Kamiyoshihara, M | 1 |
| Nagashima, T | 1 |
| Ibe, T | 1 |
| Takeyoshi, I | 1 |
| Nojiri, T | 1 |
| Yamamoto, K | 1 |
| Maeda, H | 1 |
| Takeuchi, Y | 1 |
| Funakoshi, Y | 1 |
| Maekura, R | 1 |
| Okumura, M | 1 |
| Fujii, M | 1 |
| Bessho, R | 1 |
| Ochi, M | 1 |
| Terajima, K | 2 |
| Takeda, S | 3 |
| Takamoto, S | 1 |
| Namiki, A | 1 |
| Kasanuki, H | 1 |
| Hosoda, S | 1 |
| Akaishi, M | 1 |
| Sakaguchi, T | 1 |
| Miyagawa, S | 1 |
| Yoshikawa, Y | 1 |
| Fukushima, S | 1 |
| Saito, S | 1 |
| Ueno, T | 1 |
| Kuratani, T | 1 |
| Sawa, Y | 1 |
| Kunimoto, S | 1 |
| Ito, N | 1 |
| Morishige, N | 1 |
| Hayashida, Y | 1 |
| Kuwahara, G | 1 |
| Sukehiro, Y | 1 |
| Teratani, H | 1 |
| Sakaguchi, M | 1 |
| Sasaki, Y | 1 |
| Hirai, H | 1 |
| Hosono, M | 1 |
| Nakahira, A | 1 |
| Seo, H | 1 |
| Suehiro, S | 1 |
| Nakanishi, K | 1 |
| Kim, C | 1 |
| Kohda, S | 1 |
| Konishi, R | 1 |
| Maeda, R | 1 |
| Endo, I | 1 |
| Inoue, N | 1 |
| Seo, N | 1 |
| Furuhashi, K | 1 |
| Maruyama, K | 1 |
| Sakai, H | 1 |
| Igarashi, K | 1 |
| Imai, M | 1 |
| Miura, K | 1 |
| Kanai, M | 1 |
| Okazaki, A | 1 |
| Hazanov, N | 1 |
| Somin, M | 1 |
| Attali, M | 1 |
| Beilinson, N | 1 |
| Thaler, M | 1 |
| Mouallem, M | 1 |
| Maor, Y | 1 |
| Zaks, N | 1 |
| Malnick, S | 1 |
| Mayahara, T | 1 |
| Goto, M | 1 |
| Sato, M | 1 |
| Kanazawa, T | 1 |
| Isomine, S | 1 |
| Nakajima, H | 1 |
| Sakaida, K | 1 |
| Yoshida, Y | 2 |
| Hongo, T | 2 |
| Ogawa, R | 1 |
| Satoh, N | 1 |
| Kobayashi, K | 1 |
| Kitoh, T | 1 |
| Otagiri, T | 1 |
| Ozmen, N | 1 |
| Cebeci, BS | 1 |
| Kardesoglu, E | 1 |
| Atasoyu, EM | 1 |
| Unver, S | 1 |
| Celik, T | 1 |
| Aparci, M | 1 |
| Dincturk, M | 1 |
| Sato, C | 1 |
| Akada, S | 1 |
| Miyagi, Y | 1 |
| Aranda-Michel, J | 1 |
| Morgan, SL | 1 |
| Kuruma, A | 1 |
| Yashima, M | 1 |
| Saitoh, H | 1 |
| Ino, T | 1 |
| Endoh, Y | 1 |
| Hayakawa, H | 1 |
| Chavaz, A | 1 |
| Balant, L | 1 |
| Fabre, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)[NCT02929329] | Phase 3 | 8,256 participants (Actual) | Interventional | 2017-01-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire with a 2-week recall period that includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score. Scores are represented on a 0-to-100-point scale, where lower scores represent more frequent and severe symptoms and scores of 100 indicate no symptoms.~The change from baseline in KCCQ TSS was analyzed separately for each randomization setting (inpatient and outpatient).~Least squares means are from the mixed model which includes baseline total symptom score value, region, baseline eGFR, scheduled visit, treatment group and interaction of treatment with scheduled visit as covariates." (NCT02929329)
Timeframe: Baseline and Week 24
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo: Oupatients | 6.29 |
| Omecamtiv Mecarbil: Outpatients | 5.83 |
| Placebo: Inpatients | 21.15 |
| Omecamtiv Mecarbil: Inpatients | 23.65 |
"All events were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.~Time to all-cause death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with an event are reported. Events that occurred up to the earliest of last confirmed survival status date or analysis cut-off date (07 August 2020) are included." (NCT02929329)
Timeframe: From randomization up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 25.9 |
| Omecamtiv Mecarbil | 25.9 |
"Cardiovascular death includes acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.~All deaths were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.~Time to cardiovascular death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 19.4 |
| Omecamtiv Mecarbil | 19.6 |
"The primary outcome was a composite of a heart-failure (HF) event or cardiovascular (CV) death, whichever occurred first, in a time-to-event analysis.~A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy.~All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at the Duke Clinical Research Institute, using standardized definitions based on the recent American College of Cardiology/American Heart Association (ACC/AHA) standards for endpoint definitions in cardiovascular clinical trials.~Time to cardiovascular death or first HF event was analyzed using Kaplan-Meier (KM) methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 39.1 |
| Omecamtiv Mecarbil | 37.0 |
"A HF hospitalization is defined as an event that met all of the following criteria:~The participant was admitted to the hospital with a primary diagnosis of HF;~The length of stay in the hospital extended for at least 24 hours;~The participant exhibited documented new or worsening symptoms due to HF on presentation;~The participant had objective evidence of new or worsening HF;~The participant received initiation or intensification of treatment specifically for HF, including an intravenous diuretic or vasoactive agent, mechanical or surgical intervention, or mechanical fluid removal.~Events were adjudicated by an independent external CEC at the Duke Clinical Research Institute using standardized definitions based on the ACC/AHA standards for endpoint definitions in CV clinical trials.~Time to first HF hospitalization was analyzed using KM methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 28.7 |
| Omecamtiv Mecarbil | 27.7 |
11 reviews available for urea and Auricular Fibrillation
| Article | Year |
|---|---|
[The Role of Ultrarapid Acting Betablocker Esmolol and Landiolol in Critically Ill Patients].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Critical Illness; Humans; Morpholines; Propanolami | 2019 |
Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.
Topics: Atrial Fibrillation; Cost-Benefit Analysis; Delivery of Health Care; Germany; Humans; Morpholines; P | 2020 |
Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Japan; Morpholines; Urea | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis.
Topics: Atrial Fibrillation; Humans; Morpholines; Postoperative Complications; Treatment Outcome; Urea | 2022 |
Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Do | 2017 |
Landiolol: A Review in Tachyarrhythmias.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Dose-Respo | 2018 |
Landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Incidence; Morphol | 2014 |
Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Incidence; Ja | 2014 |
Are beta-blockers effective for preventing post-coronary artery bypass grafting atrial fibrillation? Direct and network meta-analyses.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bayes Theorem; Bisoprolol; Coronary Artery Bypass; | 2016 |
Could atrial natriuretic peptide be a useful drug therapy for high-risk patients after cardiac surgery?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Benchmarking; Cardiac Surgic | 2009 |
21 trials available for urea and Auricular Fibrillation
| Article | Year |
|---|---|
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Topics: Atrial Fibrillation; Atrial Flutter; Digoxin; Heart Failure; Humans; Quality of Life; Stroke Volume; | 2022 |
Effects of Landiolol on Macrocirculatory Parameters and Left and Right Ventricular Performances Following Cardiac Surgery: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Morpholines; | 2022 |
Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Humans; Middle Aged; Morpholines; Pilo | 2019 |
Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Surgical P | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Microcirculatory effects of landiolol: a double-blind, randomised, controlled study after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedure | 2021 |
The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytokines; Esophagea | 2017 |
Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Squ | 2017 |
Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribut | 2014 |
Perioperative use of a beta blocker in coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrilla | 2013 |
Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug | 2014 |
Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventric
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; F | 2015 |
Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia, General; Atrial Fibrillation; Dose-Response Relations | 2016 |
Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschoo | 2017 |
Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypa | 2011 |
Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Coronary A | 2012 |
Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiac Surgical P | 2012 |
Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; | 2012 |
Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Do | 2012 |
Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follow- | 2012 |
Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2000 |
60 other studies available for urea and Auricular Fibrillation
| Article | Year |
|---|---|
Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment.
Topics: Atrial Fibrillation; Heart Failure; Hospital Mortality; Humans; Morpholines; Prognosis; Prospective | 2022 |
The application of landiolol in the cardiovascular and intensive care
Topics: Atrial Fibrillation; Critical Care; Heart Rate; Humans; Morpholines; Myocardial Infarction; Urea | 2022 |
A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?
Topics: Atrial Fibrillation; Digoxin; Heart Failure; Humans; Urea | 2022 |
Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Child; Heart Rate; Humans; Hypotension; Infant; Pr | 2022 |
Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection.
Topics: Antidiuretic Hormone Receptor Antagonists; Aortic Dissection; Atrial Fibrillation; Diuretics; Humans | 2023 |
[Effect of Landiolol for Atrial Fibrillation after Open Heart Surgery].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; | 2023 |
A Penny Saved Should Be a Penny Earned.
Topics: Atrial Fibrillation; Cost-Benefit Analysis; Germany; Humans; Morpholines; Urea | 2020 |
Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2020 |
Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients.
Topics: Aged; Atrial Fibrillation; COVID-19 Drug Treatment; Critical Illness; Female; Heart Rate; Hospitaliz | 2021 |
Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Electrocardiography | 2021 |
Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies.
Topics: Atrial Fibrillation; Child; Humans; Infant; Morpholines; Retrospective Studies; Tachycardia; Urea | 2021 |
Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction.
Topics: Administration, Cutaneous; Administration, Intravenous; Adrenergic beta-Antagonists; Adult; Atrial F | 2017 |
[Postoperative Atrial Fibrillation in Patients who Underwent Thoracic Aortic Surgery].
Topics: Aged; Aged, 80 and over; Aorta, Thoracic; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Mo | 2018 |
Landiolol hydrochloride for preventing postoperative atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Incidence; Morpholines; Risk Factors; Urea | 2018 |
Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans; Male; Middle Aged; Morpho | 2019 |
What Determines the Response to Landiolol?
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction | 2019 |
What Determines the Response to Landiolol? - Reply.
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction | 2019 |
A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Hea | 2019 |
Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Colon; Esophageal | 2014 |
Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Drug Administrati | 2014 |
A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Female; Heart Failure; Heart | 2014 |
Effect of landiolol hydrochloride after off-pump coronary artery bypass.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypa | 2013 |
The role of β-blockers in cardiac perioperative management.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dr | 2014 |
Preventive effect of intraoperative landiolol administration on atrial fibrillation after off-pump coronary artery bypass grafting.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Coronary Artery Bypass, O | 2014 |
Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium C | 2014 |
Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Atrial Fibrillation; Atr | 2015 |
Thyroid Storm with Heart Failure Treated with a Short-acting Beta-adrenoreceptor Blocker, Landiolol Hydrochloride.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electric Countershock; Female; Heart Failure | 2015 |
Might a beta blocker finally provide some relief from postoperative atrial fibrillation?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Morpholines; Postoperative Compli | 2015 |
An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension.
Topics: Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Biological Availability; Cardiomyopathy | 2015 |
Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Female; Humans; Male; | 2016 |
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies; | 2016 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; F | 2017 |
Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
Topics: Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Male; Morpholin | 2016 |
Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2016 |
Prognostic indices among hypertensive heart failure patients in Nigeria: the roles of 24-hour Holter electrocardiography and 6-minute walk test.
Topics: Aged; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Echocardiography, Doppler; Electroca | 2017 |
Use of landiolol for treatment of atrial fibrillation in a patient with terminal cancer.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Colonic Neoplasms; Female; Humans; Morpholines; T | 2010 |
[Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection].
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2008 |
Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopulmonary Bypa | 2009 |
Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2009 |
Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Fe | 2009 |
Conversion of atrial flutter to sinus rhythm during landiolol infusion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Hernia, Inguinal; Humans; Infusions, Intravenous; | 2010 |
[Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Female; He | 2010 |
[Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2010 |
[Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Female; Hu | 2010 |
Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter | 2012 |
Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Female; Hemodynamics; Humans; Infusions, Int | 2011 |
Intravenous infusion of ultra-short-acting β-blocker for postoperative atrial fibrillation is the one of choice.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiovascular Agents | 2012 |
Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2013 |
Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Heart Valve Prosthesis Im | 2013 |
[Successful control of rapid heart rate in a patient with atrial fibrillation by continuous intravenous administration of landiolol hydrochloride].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Male; Morpholines | 2003 |
[Clinical experience of landiolol for the treatment of intraoperative rapid atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Cardiopulmonary Bypass; Cardiovascular Surgi | 2004 |
[Perioperative heart rate control with landiolol for a patient with rapid atrial fibrillation complicated with low cardiac function].
Topics: Anesthesia, Epidural; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardi | 2004 |
Acute renal embolism. Forty-four cases of renal infarction in patients with atrial fibrillation.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Biomarkers; Creatinine; | 2004 |
Conversion of atrial fibrillation to sinus rhythm during landiolol infusion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Infusions, Intravenous; Intracran | 2004 |
Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Hemodynamics; Humans; Intraoperative Complication | 2005 |
[Effect of landiolol on heart rate control of atrial fibrillation in a patient with sick sinus syndrome under ventricular pacing].
Topics: Anesthesia, General; Anti-Asthmatic Agents; Arthroplasty, Replacement; Atrial Fibrillation; Cardiac | 2006 |
Relationship between P-wave dispersion and effective hemodialysis in chronic hemodialysis patients.
Topics: Atrial Fibrillation; Creatinine; Electric Impedance; Electrocardiography; Female; Heart Conduction S | 2007 |
Clinical role and efficacy of landiolol in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Catecholamines; Female; Hear | 2008 |
Overfeeding in a patient with Kwashiorkor syndrome.
Topics: Atrial Fibrillation; Energy Intake; Female; Humans; Hypercapnia; Kwashiorkor; Magnesium Deficiency; | 1996 |
[Blood digoxin level and digitalization].
Topics: Aged; Atrial Fibrillation; Creatinine; Digoxin; Dose-Response Relationship, Drug; Electrocardiograph | 1974 |